UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): **January 11, 2024**

AngioDynamics, Inc.

(Exact Name of Registrant as Specified in Charter)

Delaware	**000-50761**	**11-3146460**
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)
14 Plaza Drive Latham, New York		**12110**
(Address of Principal Executive Offices)		(Zip Code)

(518) 795-1400
(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2 (b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4 (c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value $0.01 per share	ANGO	NASDAQ Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 – Regulation FD Disclosure.

On January 11, 2024, James Clemmer, President and Chief Executive Officer of AngioDynamics, Inc. ("AngioDynamics"), will present at the J.P. Morgan 42nd Annual Healthcare Conference. The presentation slides are furnished herewith as Exhibit 99.1.

The presentation slides furnished pursuant to Item 7.01 of this Form 8-K (including Exhibit 99.1) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities under that Section. Furthermore, the presentation slides shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act.

Forward-Looking Statements

This document and its attachments contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics' expected future financial position, results of operations, cash flows, business strategy, budgets, projected costs, capital expenditures, products, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include the words such as "expects," "reaffirms," "intends," "anticipates," "plans," "believes," "seeks," "estimates," "projects", "optimistic," or variations of such words and similar expressions, are forward-looking statements. These forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties. Investors are cautioned that actual events or results may differ materially from AngioDynamics' expectations, expressed or implied. Factors that may affect the actual results achieved by AngioDynamics include, without limitation, the scale and scope of the COVID-19 global pandemic, the ability of AngioDynamics to develop its existing and new products, technological advances and patents attained by competitors, infringement of AngioDynamics' technology or assertions that AngioDynamics' technology infringes the technology of third parties, the ability of AngioDynamics to effectively compete against competitors that have substantially greater resources, future actions by the FDA or other regulatory agencies, domestic and foreign health care reforms and government regulations, results of pending or future clinical trials, overall economic conditions (including inflation, labor shortages and supply chain challenges including the cost and availability of raw materials), the results of on-going litigation, challenges with respect to third-party distributors or joint venture partners or collaborators, the results of sales efforts, the effects of product recalls and product liability claims, changes in key personnel, the ability of AngioDynamics to execute on strategic initiatives, the effects of economic, credit and capital market conditions, general market conditions, market acceptance, foreign currency exchange rate fluctuations, the effects on pricing from group purchasing organizations and competition, the ability of AngioDynamics to obtain regulatory clearances or approval of its products, or to integrate acquired businesses, as well as the risk factors listed from time to time in AngioDynamics' SEC filings, including but not limited to its Annual Report on Form 10-K for the year ended May 31, 2023. AngioDynamics does not assume any obligation to publicly update or revise any forward-looking statements for any reason.

Item 9.01 – Financial Statements and Exhibits.

(d) *Exhibits*.

Exhibit No.	Description
99.1	Presentation slides for the J.P. Morgan 42nd Annual Healthcare Conference, dated January 11, 2024

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ANGIODYNAMICS, INC.
(Registrant)

Date: January 11, 2024

By: /s/ Stephen A. Trowbridge
Name: Stephen A. Trowbridge
Title: Executive Vice President and Chief Financial Officer

Exhibit 99.1


angiodynamics
J.P. Morgan
Healthcare Conference
January 11, 2024
Jim Clemmer, President & CEO


AngioDynamics
A medical technology platform company focused on a select group of large, high growth markets where meaningful treatment gaps exist in current standard of care.
We are transforming our portfolio to be a company focused on investing our resources on innovative technologies backed by science and clinical data. Our technologies positively impact treatment options and patients' quality of life.
AURYON
ANGIOVAC
ALPHAVAC
NanoKnife

AngioDynamics

Cardiovascular disease and cancer have the highest morbidity and mortality worldwide

Global Cardiovascular Disease Burden[1]

523M diagnosed in 2020
~19 million deaths

Cardiovascular Disease causes 1 in 3 deaths globally

Global Cancer Burden[2]

19.3M diagnosed in 2020
~10 million deaths

Cancer causes 1 in 6 deaths globally

1. https://professional.heart.org/-/media/PHD-Files-2/Science-News/2/2022-Heart-and-Stroke-Stat-Update/2022-Stat-Update-factsheet-Global-Burden-of-Disease.pdf; https://www.cdc.gov/pcd/issues/2022/22_0347.htm
2. https://acsjournals.onlinelibrary.wiley.com/doi/10.3322/caac.21660#:~:text=Worldwide%2C%20an%20estimated%2019.3,of%20cancer%20deaths.

MedTech Markets

Targeted segments have attractive underpenetrated addressable markets

ANGIOVAC ALPHAVAC
Cardiac Thrombus & Emboli
$825M TAM

ALPHAVAC
Pulmonary Embolism
$2.9B TAM

NanoKnife
Prostate Cancer
$2B TAM

AURYON ALPHAVAC
Deep Vein Thrombosis
$3B TAM

AURYON
Peripheral Arterial Disease
$1.1B TAM

*AlphaVac PE, Auryon Venous Thrombectomy/DVT, AngioVac Left Heart and Infective Endocarditis are not cleared by the US Food and Drug Administration (FDA) for these indications. In the United States, the NanoKnife System has received a 510(k) clearance by the Food and Drug Administration for use in the surgical ablation of soft tissue. The NanoKnife System has not been cleared for the treatment or therapy of a specific disease or condition.

AngioDynamics

Investments in our Med Tech platforms are funded by operating cash flows from our Med Device portfolio

Med Tech: Invest for Growth

Disease State	Latest Investment Updates
Peripheral Arterial Disease	• Radial length catheter launch Jan 2024 • Pathfinder 12 month & 24 month publications Feb & July 2024 • Below the knee study publication March 2024 • CE Mark expected May 2024 • 6 additional new product extensions/upgrades scheduled throughout 2024 • Coronary Atherectomy pre-submission (PMA) & pilot trial planned to begin in 2024
Venous Thromboembolism	• APEX complete, PE indication expected by June 2024 • CE Mark for PE expected by June 2024 • 2 additional new product extensions/upgrades scheduled throughout 2024 • IDE clinical trial for Auryon DVT to begin in late 2024
Cardiac Thrombus & Emboli	• Begin study for Infective Endocarditis indication in 2024
Prostate	• PRESERVE Study enrolled, expected Prostate indication by December 2024

Med Device: Maintain Positioning

PICCs, Midlines & Accessories	Microwave & Radiofrequency Ablation
Diagnostic Catheters, Guidewires & Kits	Implantable Ports
Endovenous Laser Treatment	Radiation Treatment Stabilization Balloons

*AlphaVac PE, Auryon Venous Thrombectomy/DVT, Auryon Coronary Atherectomy, AngioVac Left Heart and Infective Endocarditis are not cleared by the US Food and Drug Administration (FDA) for these indications.
In the United States, the NanoKnife System has received a 510(k) clearance by the Food and Drug Administration for use in the surgical ablation of soft tissue.
The NanoKnife System has not been cleared for the treatment or therapy of a specific disease or condition.
The planned portfolio additions and new indications are based on management estimates and industry sources as of July 2022 and are not guarantees of future performance and are subject to risks and uncertainties including FDA clearance. Investors are cautioned that actual events or results may differ from AngioDynamics' expectations.

PAD

As of November 2023, the Auryon Atherectomy System has treated over 50,000 patients and reached $100M cumulative sales since its September 2020 launch

THE MARKET

2022 TAM

$1.1B

Source: Management estimate & Industry sources as of July 2022.

OUR SOLUTION

AURYON

- Peripheral Atherectomy

WHY IT MATTERS

Treat all levels of calcification [a-c]

- Indicated for in-stent restenosis*
- Treats above and below the knee (inc. below the ankle)

*2.0mm and 2.35mm catheters are indicated for ISR.

Protective of vessel wall [c-e]

- Targeted biological reactions to address risk of perforations
- Built-in aspiration to address risk of embolization†

†Built-in aspiration available with the 2.0-and 2.35-mm catheters.

Designed for hospital and lab [a-c, f]

- Portable, 110V outlet, low noise, touch screen
- Debulk in fewer passes

a-f See reference page

"We've always known that Auryon's technology is one-of-a-kind and unmatched. With the new [hydrophilic coating], we should be able to prove this – case after case after case"

– Dr. Curtis Anderson, Vascular & Interventional Radiologist

Thrombus Management

Our differentiated technology platforms offer potential treatment solutions across multiple disease states

THE MARKET

VTE
PE
Pulmonary Embolism
DVT
Deep Vein Thrombosis

+

Cardiac
TVIE
Tricuspid Valve Infective Endocarditis
LV
Lead Vegetation
RA
Right Atrial Thrombus

2022 TAM
$6.7B

OUR SOLUTION

ANGIOVAC
- Right Heart and Left Heart* removal of cardiac thrombus

ALPHAVAC
- Large Vessel Venous Thrombectomy/DVT
- Pulmonary Embolism*

AURYON
- Small Vessel Venous Thrombectomy/DVT*

WHY IT MATTERS

- Only solution on the market with *continuous aspiration* and *simultaneous reinfusion* of filtered blood
- Aspirates large clot burden

- Controlled aspiration
- Aspirates large clot burden
- APEX-AV study for PE

- Auryon's low profile + laser + aspiration, make it a compelling and simple technology to effectively ablate & remove thrombus with the legs

Source: Management estimate & industry sources as of July 2022.
*AlphaVac PE, Auryon Venous Thrombectomy/DVT, and AngioVac Left Heart and Infective Endocarditis are not cleared by the US FDA for these indications.

Thrombus Management

All-purpose technology platforms targeted at peripheral and cardiovascular thrombolytic events, including small and large vessels



Large Vessel

Small Vessel



RADIOPAQUE MARKERS
Better Tip Visibility

LARGE END HOLE ASPIRATION
42FR & 30FR Opening

PROPRIETARY FUNNEL DESIGN
Allows for Significant Clot Removal

MULTIPLE TIP ANGLES
20°, 85°, 180°

ANGIOVAC

The **AngioVac** System allows for the **continuous aspiration** of embolic material such as thrombi and emboli from the venous system while **simultaneously reinfusing** the patient's own filtered blood to limit procedural blood loss

ALPHAVAC

The **AlphaVac** System allows for the **controlled aspiration** of embolic material such as thrombi and emboli from the venous system



AURYON

POWERFUL
355 nm laser is designed to deliver an optimized wavelength, pulse width, and amplitude to restore flow in occluded vessels[c, d, g]

PRECISE
Protective of vessel wall[c-e]

ADAPTABLE
Potential to treat all types of small vessel DVT*

c-g See reference page
*Auryon Venous Thrombectomy/DVT is not cleared by the US FDA for this indication.

NanoKnife Prostate Initiative*

Over 505,000 men with prostate cancer could be treated with this technology

THE MARKET

2023 Global TAM

$2B

OUR SOLUTION

NanoKnife

- Focal Therapy

WHY IT MATTERS

Targeted: Short electric pulses destroy cells without relying on extreme heat or cold and spare vital structures within the ablation zone

Quality of Life: Better preserves urinary control and erectile function

Versatile: Can be used in all segments of the prostate for primary and recurrent disease

Fast: Minimally invasive treatment that is delivered in a single session

Preserves future treatment options

*IDE Study in progress; enrollment completed

In the United States, the NanoKnife System has received a 510(k) clearance by the Food and Drug Administration for use in the surgical ablation of soft tissue. The NanoKnife System has not been cleared for the treatment or therapy of a specific disease or condition.

Market Source: Management estimate & industry sources as of July 2022

International Expansion Plan

Expanding our business reach in targeted regions, markets & countries

Aligning our Go-to-Market strategy to the different regions, markets & countries, utilizing new partnerships where appropriate to maximize growth

Preparing for CE Mark and other selected international launches of both the Auryon System and the AlphaVac F18[85] System

- Auryon CE Mark expected 1H of calendar 2024
- AlphaVac F18[85] System CE Mark expected 1H of calendar 2024

Continue to increase our global presence through our series of life symposiums which has attracted interest from global key opinion leaders who are gaining more access to our technologies

Corporate Developments – Q2 and YTD FY24

Continued focused investment in our 3 key Med Tech platforms: Auryon, Thrombus Management & NanoKnife

Q2 FY24

Revenue
$79.1 mil
Pro Forma Revenue Growth*
2.7%

Med Tech up **3.5%**
Med Device up 2.3%*

$11.4 million in **Auryon** sales; growth of 12.9% YOY

Mechanical Thrombectomy down 4.7% YOY
$1.9 million in AlphaVac sales
AngioVac sales declined 10.8% YOY

NanoKnife disposables down 3.6% YOY

YTD FY24

Pro Forma Revenue*
$157.1 mil
Pro Forma Revenue Growth*
4.2%

Med Tech up **8.3%**
Med Device up 2.3%*

$22.5 million in **Auryon** sales; growth of 18.9% YOY

Mechanical Thrombectomy down 5.3% YOY
$3.7 million in AlphaVac sales
AngioVac sales declined 9.2% YOY

12.9% YOY growth in **NanoKnife** disposables

* On a pro forma basis, excluding the sale of Dialysis and BioSentry

IDE
Clinical Studies and Pathway Expansion

PRESERVE study for the treatment of prostate cancer with NanoKnife **completed enrollment** in July 2023

APEX AV study for the treatment of pulmonary embolism with AlphaVac F18[MS] System
- **Completed enrollment** in December 2023
- Submission to the FDA planned in early calendar 2024

Q2
Highlights and Operational Developments

Initiated **restructuring** of manufacturing footprint to a fully outsourced model

Continued **portfolio optimization** initiatives

Full-year adjusted EPS **profitability** expected in FY27

Cumulative **Auryon** sales of over **$100.0 million** achieved in November

FY24 Revised Guidance

	Guidance*	Revised Guidance*
Revenue	$328 - $333 million	$320 - $325 million
Gross Margin	50.0% - 52.0%	49.0% - 51.0%
Med Tech	63.0% – 65.0%	61.0% – 63.0%
Med Device	43.0% - 45.0%	43.0% - 45.0%
Adjusted EPS	($0.28) – ($0.34)	($0.35) – ($0.42)

* FY23 pro forma results excluding the divested assets were $306.3 million for revenue, 50.5% for gross margin and adjusted loss per share of $0.43.


angiodynamics
J.P. Morgan
Healthcare Conference
January 11, 2024
Jim Clemmer, President & CEO

Auryon References

a. Rundback J, Chandra P, Brodmann M, Weinstock B, Sedillo G, Cawich I, et al. Novel laser-based catheter for peripheral atherectomy: 6-month results from the Eximo Medical B-Laser™ IDE study. Catheter Cardiovasc Interv. 2019;1-8.

b. Shammas NW, Chandra P, Brodmann M, Weinstock B, Sedillo G, Cawich I, et al. Acute and 30-day safety and effectiveness evaluation of Eximo Medical's B-Laser™, a novel atherectomy device, in subjects affected with infrainguinal peripheral arterial disease: Results of the EX-PAD-03 trial. Cardiovas Revasc Med. 2020;21(1):86-92.

c. Auryon. Instructions for use. AngioDynamics; 2019.

d. Herzog A, Bogdan S, Gilkson M, Ishaaya AA, Love C. Selective tissue ablation using laser radiation at 355 nm in lead extraction by a hybrid catheter; a preliminary report. Lasers Surg Med. 2016;48(3):281-287.

e. Herzog A, Steinberg I, Galsenberg E, Nomberg R, Ishaaya AA. A route to laser angioplasty in the presence of fluoroscopy contrast media, using a nanosecond-pulsed 355-nm laser. IEEE J Sel Top Quantum Electron. 2016;22(3):342-347.

f. Kuczmik W, Kruszyna L, Stanisic MG, Dzieciuchowicz L, Ziaja K, Zelawski W, et al. Laser atherectomy using the novel B-Laser™ catheter, for the treatment of femoropopliteal lesions: twelve-month results from the EX-PAD-01 study. Not yet published.

g. Vogel A, Venugopalan V. Mechanisms of pulsed laser ablation of biological tissues. Chem Rev. 2003;103(2):577-644.